SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001600620-23-000010
Filing Date
2023-05-04
Accepted
2023-05-04 06:06:27
Documents
14
Period of Report
2023-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K auph-20230504.htm   iXBRL 8-K 37375
2 EX-99.1 exhibit991_q12023pressrele.htm EX-99.1 102455
6 aurinalogo.jpg GRAPHIC 11010
  Complete submission text file 0001600620-23-000010.txt   299249

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20230504.xsd EX-101.SCH 1936
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20230504_lab.xml EX-101.LAB 23924
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20230504_pre.xml EX-101.PRE 12622
8 EXTRACTED XBRL INSTANCE DOCUMENT auph-20230504_htm.xml XML 10829
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 23886228
SIC: 2834 Pharmaceutical Preparations